TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nova Eye Medical ( (AU:EYE) ) has provided an announcement.
Nova Eye Medical Limited announced a correction in their Quarterly Activities and Appendix 4C Cash Flow Report for June 2025, adjusting the cash and cash equivalents figure to A$5,054,000. The company reported a record full-year revenue of A$29.2 million for FY25, a 23% increase from the previous year, with significant sales growth in the second half. The glaucoma segment achieved a positive EBITDA in the second half of FY25, and the company forecasts sales revenue between US$21 million to US$24 million for FY26, excluding China, aiming for breakeven EBITDA in the first half of FY26.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company specializing in ophthalmic treatment technologies and devices. Their products include the iTrack™ Advance, a minimally invasive glaucoma surgical device, and the Molteno3® glaucoma drainage device platform. The company operates globally with sales headquarters in Fremont, California, and manufacturing facilities in California and New Zealand.
Average Trading Volume: 466,877
Technical Sentiment Signal: Hold
Current Market Cap: A$42.62M
For detailed information about EYE stock, go to TipRanks’ Stock Analysis page.